Abstract：
BACKGROUND: To evaluate the clinical efficacy of sublingual-specific immunotherapy (SLIT) and pulmonary function in children with allergic rhinitis and asthma before and after puberty.
METHODS: This retrospective analysis included 136 patients aged 4-18 years with allergic asthma and rhinitis who received two years of SLIT treatment. Patients were divided into two groups based on age: the prepubertal group (4-10 years old) and the pubertal group (11-18 years old). After half a year, one year, and two years of SLIT, the total nasal symptom score (TNSS), total rhinitis medication score (TRMS), daytime asthma symptom score (DASS), nighttime asthma symptom score (NASS), total asthma medication score (TAMS), asthma control test (ACT), and peak expiratory flow rate (PEF%) were evaluated and compared with the baseline before treatment.
RESULTS: In both groups, TNSS, TRMS, DASS, NASS, TAMS, ACT, and PEF% improved significantly after half a year, one year, and two years of SLIT treatment. After half a year of treatment, prepubertal patients showed better therapy for TNSS, DASS, NASS, and TAMS compared to the pubertal group. The TAMS of the pubertal group was higher than that of the prepubertal group after one year of treatment. Finally, the PEF% showed better therapy compared to the pubertal group.
CONCLUSIONS: SLIT treatment with Dermatophagoides farinae drops can effectively control the symptoms of rhinitis and asthma in children with allergic rhinitis and asthma before and after puberty, reduce the use of symptomatic drugs, significantly improve the pulmonary function of patients, and have better effects on asthma in prepubertal children than in adolescents.
METHODS: This retrospective analysis included 136 patients aged 4-18 years with allergic asthma and rhinitis who received two years of SLIT treatment. Patients were divided into two groups based on age: the prepubertal group (4-10 years old) and the pubertal group (11-18 years old). After half a year, one year, and two years of SLIT, the total nasal symptom score (TNSS), total rhinitis medication score (TRMS), daytime asthma symptom score (DASS), nighttime asthma symptom score (NASS), total asthma medication score (TAMS), asthma control test (ACT), and peak expiratory flow rate (PEF%) were evaluated and compared with the baseline before treatment.
RESULTS: In both groups, TNSS, TRMS, DASS, NASS, TAMS, ACT, and PEF% improved significantly after half a year, one year, and two years of SLIT treatment. After half a year of treatment, prepubertal patients showed better therapy for TNSS, DASS, NASS, and TAMS compared to the pubertal group. The TAMS of the pubertal group was higher than that of the prepubertal group after one year of treatment. Finally, the PEF% showed better therapy compared to the pubertal group.
CONCLUSIONS: SLIT treatment with Dermatophagoides farinae drops can effectively control the symptoms of rhinitis and asthma in children with allergic rhinitis and asthma before and after puberty, reduce the use of symptomatic drugs, significantly improve the pulmonary function of patients, and have better effects on asthma in prepubertal children than in adolescents.
摘要：
背景：评估舌下特异性免疫治疗（SLIT）在儿童过敏性鼻炎和哮喘青春期前后的临床疗效和肺功能。
方法：这项回顾性分析包括136名年龄在4-18岁的过敏性哮喘和鼻炎患者，他们接受了两年的SLIT治疗。根据年龄将患者分为两组：青春期前组（4-10岁）和青春期组（11-18岁）。半年后，一年,和两年的缝纫，鼻部症状总评分（TNSS），总鼻炎药物评分（TRMS），日间哮喘症状评分（DASS），夜间哮喘症状评分（NASS），总哮喘药物评分（TAMS），哮喘控制测试（ACT），评估呼气峰流速(PEF%),并与治疗前基线进行比较.
结果：在两组中，TNSS,TRMS,DASS,NASS,TAMS,ACT,PEF%在半年后显著提高，一年,和两年的SLIT治疗。经过半年的治疗,青春期前患者对TNSS的治疗效果更好，DASS,NASS,和TAMS与青春期组相比。治疗一年后，青春期组的TAMS高于青春期前组。最后,与青春期组相比,PEF%显示出更好的治疗效果.
结论：SLIT治疗过敏性鼻炎和哮喘患儿青春期前后的鼻炎和哮喘症状可有效控制。减少对症药物的使用，显著改善患者的肺功能，对青春期前儿童哮喘的治疗效果优于青少年。
方法：这项回顾性分析包括136名年龄在4-18岁的过敏性哮喘和鼻炎患者，他们接受了两年的SLIT治疗。根据年龄将患者分为两组：青春期前组（4-10岁）和青春期组（11-18岁）。半年后，一年,和两年的缝纫，鼻部症状总评分（TNSS），总鼻炎药物评分（TRMS），日间哮喘症状评分（DASS），夜间哮喘症状评分（NASS），总哮喘药物评分（TAMS），哮喘控制测试（ACT），评估呼气峰流速(PEF%),并与治疗前基线进行比较.
结果：在两组中，TNSS,TRMS,DASS,NASS,TAMS,ACT,PEF%在半年后显著提高，一年,和两年的SLIT治疗。经过半年的治疗,青春期前患者对TNSS的治疗效果更好，DASS,NASS,和TAMS与青春期组相比。治疗一年后，青春期组的TAMS高于青春期前组。最后,与青春期组相比,PEF%显示出更好的治疗效果.
结论：SLIT治疗过敏性鼻炎和哮喘患儿青春期前后的鼻炎和哮喘症状可有效控制。减少对症药物的使用，显著改善患者的肺功能，对青春期前儿童哮喘的治疗效果优于青少年。
